Obesity and extreme obesity, manifest by ages 20–24 years, continuing through 32–41 years in women, should alert physicians to the diagnostic likelihood of polycystic ovary syndrome as a reversible underlying endocrinopathy

Glueck, Charles J.; Dharashivkar, S.; Wang, Ping; Zhu, Bing; Gartside, Peter S.; Tracy, Trent; Sieve, L.

doi:10.1016/j.ejogrb.2005.03.010

Cited by 94 publications

(62 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, it is not clear whether there is any difference between the most appropriate adiposity indexes of women with PCOS and the normo-ovulatory non-hirsute women (8). Several efforts have been made to compare the optimum obesity marker for women with PCOS with normal control subjects (8,9,10), but the majority of these studies are based on the measurements performed in women with PCOS referred to clinics (42,43,44,45,46), which may not yield reliable estimations. In addition to small samples, these studies are restricted by the lack of comparison of various available adiposity markers.…”

Section: Discussionmentioning

confidence: 99%

Comparison of various adiposity indexes in women with polycystic ovary syndrome and normo-ovulatory non-hirsute women: a population-based study

Tehrani

Minooee

Azizi

2014

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: Insulin resistance (IR) and metabolic disorders are common in polycystic ovary syndrome (PCOS). However, it is still not clear which adiposity marker could precisely predict metabolic syndrome (MetS) in women with PCOS and whether these indexes are different in normo-ovulatory non-hirsute women. Design: A case-control study was conducted on a total of 175 Iranian subjects with PCOS and 525 normal control subjects, aged 18-45 years. Methods: Waist circumference (WC), BMI, waist-to-hip ratio, lipid accumulation product (LAP) index, and visceral adiposity index (VAI) were examined and the homeostasis model assessment index was calculated. MetS was defined according to the joint interim statement. The receiver operating characteristic curves were used to evaluate the extent to which measures of adiposity can predict IR and MetS risk. Results: LAP index and VAI are two indicators (sensitivity and PPV of 70% (LAP index) and 60% (VAI), and 80% (LAP index) and 83% (VAI) respectively) that best predict IR in women with PCOS. Among healthy women, the LAP index and WC were better markers (sensitivity and PPV of 78% (LAP index) and 75% (VAI), and 82% (LAP index) and 81% (VAI) respectively). The two most reliable indicators for prediction of MetS among PCOS and normal women were the WC and VAI (sensitivity and PPV of 83% (WC) and 81% (VAI), and 97% (WC) and 95% (VAI) respectively) and the VAI and LAP index (sensitivity and PPV of 88% (VAI) and 83% (LAP index), and 98% (VAI) and 98% (LAP index) respectively) respectively. Conclusions: While the appropriate adiposity indicators and their optimum cutoff values vary in women with PCOS, compared with the normal control subjects, the LAP index is an easily obtainable index that might be useful for screening of cardiometabolic complications among both groups.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of various adiposity indexes in women with polycystic ovary syndrome and normo-ovulatory non-hirsute women: a population-based study

Tehrani

Minooee

Azizi

2014

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Beginning with the original description of what is now known as PCOS by Stein and Leventhal (5), much of what we know today regarding the phenotype of PCOS, including the prevalence of obesity in the disorder, stems mostly from the study of populations referred (self or otherwise) for care (5)(6)(7). Referral to a medical practice, particularly tertiary care centers, can be highly influenced by the degree of patient concern for symptoms, awareness of the disorder, socioeconomic status, and access to medical care.…”

mentioning

confidence: 99%

Referral Bias in Defining the Phenotype and Prevalence of Obesity in Polycystic Ovary Syndrome

Ezeh

Yildiz

Azziz

2013

The Journal of Clinical Endocrinology &Amp; Metabolism

160

107

View full text Add to dashboard Cite

show abstract

“…The prevalence of visceral obesity in women with PCOS varies between 61 and 76% [69]. As in MeS, visceral obesity in PCOS is associated with elevated levels of LDL, triglycerides, and cholesterol as well as decreased levels of HDL and results in an increased risk of arteriosclerosis [70].…”

Section: Endocrine Systemmentioning

confidence: 99%

Clinical Scenario of the Metabolic Syndrome

et al. 2016

View full text Add to dashboard Cite

The term metabolic syndrome (MeS) refers to a cluster of associated symptoms composed of impaired fasting glucose, abdominal obesity, hypertension, and dyslipidemia. MeS is associated with an increased risk of cardiovascular and diabetes-associated morbidity and mortality. The increased amount of visceral fat together with a chronic inflammatory state predisposes to the development of arteriosclerosis. Furthermore, insulin resistance (IR) and dyslipidemia are associated with fatty liver disease. In addition, MeS is linked to non-cardiovascular diseases such as cancer as well as psychiatric or endocrine disorders. Here, we discuss the clinical impact of MeS in cardiovascular and non-cardiovascular diseases to highlight the importance of prevention, early diagnosis, and multifactorial treatment of high-risk individuals.

show abstract

Obesity and extreme obesity, manifest by ages 20–24 years, continuing through 32–41 years in women, should alert physicians to the diagnostic likelihood of polycystic ovary syndrome as a reversible underlying endocrinopathy

Cited by 94 publications

References 34 publications

Comparison of various adiposity indexes in women with polycystic ovary syndrome and normo-ovulatory non-hirsute women: a population-based study

Comparison of various adiposity indexes in women with polycystic ovary syndrome and normo-ovulatory non-hirsute women: a population-based study

Referral Bias in Defining the Phenotype and Prevalence of Obesity in Polycystic Ovary Syndrome

Clinical Scenario of the Metabolic Syndrome

Contact Info

Product

Resources

About